



Contents

- Executive Summary**
- Analysis of Biotechnology Core Activities**
- New York Biotech's Financial Status**
- New York State Biotechnology Employment**
- Clinical Development**
- Government Sources of Funding for New York Biotechnology**
- Biotech's Economic Impact on New York**
- New York Biotechnology Innovation**
- Recent Significant Events in New York Biotechnology**
- New York as a Place to Build a Biotech Business**
- New York State Bioscience Academic Centers and Research Facilities**

Report Rationale and Methodology

In order to understand the status and impact of biotechnology companies in New York State, NYBA conducted an extensive study of the industry, its recent development, and its economic impact. While this survey concentrates on the biotechnology companies themselves, the biotech industry could not exist without the close collaboration and partnership of the pharmaceutical, financial and academic research communities.

Their interplay and support is crucial to the vitality of any true biotechnology center.

NYBA defines a "biotechnology company" not by the nature of the company's products, but by the technologies used to make those products. We have included companies with activities focused on the discovery, development, and commercialization of technologies that use organisms or their cellular, subcellular, or molecular components to solve problems or make products. The organizations examined in this report comprise both NYBA member companies and non-member companies operating in New York State.

Organizations covered in this report include:

- Academic institutions
- Agricultural and industrial biotech companies
- Bioinformatics companies
- Biopharmaceutical therapeutic companies
- Combinatorial chemistry companies
- Diagnostic discovery companies
- Drug delivery or formulation companies
- Molecular biology companies
- Product and service providers companies
- Protein engineering companies
- Science platform companies

Organizations excluded from this report include:

- Large pharmaceutical companies*
- Service organizations (CROs, CMOs, etc.)
- Medical device companies
- Generics manufacturing companies
- Suppliers, equipment manufacturers, and other companies ancillary to the industry
- Food supplement and nutraceutical companies
- General agriculture and veterinary companies

NYBA drew the information for this report from a variety of sources, including a targeted survey; proprietary databases and sources; corporate web sites, annual reports and press releases; and public databases and search engines. The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.

* With the exceptions of Wyeth and Bristol-Myers-Squibb, which have significant biological manufacturing and/or R&D facilities in New York State, and Pfizer, which is headquartered in New York City. In these instances, only statistics related and relevant to New York State are used, eg, New York State biologics-related employment.

Executive Summary

Dear New York Biotechnology Industry Member,

We are pleased to share with you the results of the NYBA 2007 State of the Industry Report. The contributions of our growing biotechnology industry continue to have an increasingly significant positive impact on New York's economy.

The biotechnology industry directly supported nearly 10,000 jobs in New York in 2007, representing a 66 percent increase from 6,340 jobs in 2002.

Additionally, New York biotechnology companies generated approximately \$3.4 billion in revenue in 2007, an increase of 112% over 2002 revenues of \$1.6 billion.

This growth in employment and revenues has contributed directly to the State's economy. In total, the impact of New York's broader biopharma industry is estimated to be in excess of \$4.5 billion in direct economic impact and more than \$514 million is contributed to New York through tax revenue.

New York companies benefited directly from state programs developed to support the industry, in terms of both tax incentives and direct R&D funding. This helped fuel further growth as companies hired additional staff and/or initiated capital expenditures.

NYBA is proud to support New York's biotechnology community, and we are excited by the inspiring progress the industry has seen over the past five years. Special thanks are due to key members of the State government for their support of the industry, as well as the members of the biotechnology industry for generating such impressive growth.

The report and figures that follow illustrate how the relationship between our industry and New York is generating tremendous opportunities for both.

Yours,
Robert Van Nostrand and Nathan Tinker



Robert Van Nostrand
Chief Financial Officer
AGI Dermatics Inc.
Chairman, NYBA



Nathan Tinker, Ph.D.
Executive Director
NYBA

Analysis of Biotechnology Core Activities

Through our research, NYBA has positively identified a minimum of 295 companies in New York State dedicated to biotechnology and related life science industry sectors. Of these, we have identified a diverse pool of at least 118 companies that can be strictly identified as "biotechnology." The operations of these companies cover a wide range of specialties.

- 26 New York biotechnology companies are publicly traded
- 92 are private

Biotechnology Companies in New York State, by Core Activity*

	% of total
Biopharmaceutical therapeutics	53%
Bioinformatics	20%
Diagnostic discovery	10%
Drug delivery or formulation	6%
Science platform	4%
Protein engineering	3%
Molecular biology	2%
Agricultural/Industrial biotech	1%
Other	1%
	100%

Source: NYBA, company websites, annual reports, interviews and analysis

- While more than a half of these companies focus on the development of novel therapeutic products (up from just over 33% in 2002), others are engaged in a variety of activities ranging from bioinformatics and diagnostic discovery to protein engineering and platform technologies
- For each of the 26 public biotech companies in New York State, there are over 3 private biotechnology companies

Growth in Biotechnology Companies, 2003-2007

Year	Number of Companies	% change
2003	89	--
2004	101	22%
2007	118	16.8%

Source: NYBA

New York Biotech's Financial Status

Biotechnology companies bring significant value to the economy of New York State.

In 2007, biotechnology companies in New York:

- Had combined revenues of approximately \$3.4 billion
- Spent more than \$800 million on research and development
- Operated more than 90 research, manufacturing and office facilities in the state

Market Capitalization

New York's publicly traded biotechnology companies have a combined market capitalization of approximately \$10.6 billion.*

- 3 have market capitalizations greater than \$1 billion

ImClone Systems	\$3.8 billion
OSI Pharmaceuticals	\$2.2 billion
Regeneron	\$1.6 billion

- 7 have market capitalizations between \$100 million and \$1 billion

Acorda Therapeutics	\$609 million
AMRI	\$391 million
Forticell Biosciences	\$359 million
Enzo Biochem	\$318 million
Omrix	\$267 million
Progenics Pharma	\$227 million
Antigenics	\$148 million

- 16 have market capitalizations of less than \$100 million

Revenues

Revenues generated by public New York State biotech companies totaled nearly \$3.4 billion in 2007, more than double the total 2002 revenues of \$1.6 billion for the entire New York State biotech industry.

- Top revenue producers in 2007 were

	2002 Revenues	2007 Revenues	CAGR
ImClone Systems	\$60 million	\$591 million	58%
OSI Pharmaceuticals	\$22 million	\$341 million	73%
AMRI	\$123 million	\$192 million	9%
Regeneron	\$22 million	\$125 million	42%

Collectively, public New York State biotechnology companies spent approximately \$866 million on research and development in 2007.

Top Deals of the Year

- 1. October 2007:** New York City's Bioenvision was acquired by Genzyme in an all-cash transaction for \$345 million
- 2. June/July 2007:** Acorda Therapeutics Inc. (NASDAQ:ACOR) raised \$77.5 million in a follow-on offering
- 3. September 2007:** Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) raised \$60.2 million in a follow-on offering
- 4. January 2007:** Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) raised \$42.3 million in a follow-on offering

Venture Capital

However, despite a robust and active financial community, venture capital has been hard to come by for New York biotech companies. Since 2000, New York biotech has raised over \$567 million in a total of 60 deals. With only \$29 million invested in a total of 4 deals, 2007 counts as one of the leanest years in venture capital investment to New York companies during the period.

Region	Year	Number of Deals	Total Venture Capital (\$US)
NY Metro*	2000	5	\$84,050,000
	2001	8	\$134,768,200
	2002	6	\$83,056,500
	2003	8	\$109,293,700
	2004	5	\$88,800,000
	2006	12	\$46,775,900
	2007	3	\$20,599,800
NY Metro Total		47	\$567,344,100

Upstate NY	2002	1	\$15,000,000
	2003	1	\$350,000
	2004	2	\$8,850,000
	2005	5	\$1,900,000
	2006	3	\$11,050,000
	2007	1	\$8,100,000
	Upstate NY Total		13

New York State Total since 2000: \$567,389,350

Source: PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree report based on data from Thomson Financial

New York State Biotechnology Employment

In total, these **118** companies employ more than **9,500** people in New York State. However, well over half of that number are employed by just six companies, ImClone Systems, AMRI, Wyeth, Regeneron, Taconic Farms, BMS, and OSI Pharmaceuticals.

New York State's Biotech Companies with +100 Employees

	# of employees engaged in biotech/biologicals in New York	Region
ImClone Systems	1,128	Downstate Cluster
AMRI	1,000	Capital Cluster
Wyeth Pharmaceuticals*	890	Southern Tier Cluster
Regeneron	725	Downstate Cluster/ Capital Cluster
Taconic Farms	700	Capital Cluster
Bristol-Myers-Squibb*	625	Western Cluster
OSI Pharmaceuticals	488	Downstate Cluster
Luitpold	415	Downstate Cluster
Savage Laboratories	400	Downstate Cluster
Enzo Biochem	367	Downstate Cluster
UCB Manufacturing	320	Western Cluster
Progenics	245	Downstate Cluster
Omrix	212	Downstate Cluster
Acorda	150	Downstate Cluster
Genencor	140	Western Cluster
IAVI	130	Downstate Cluster
American Bio Medica Corp	117	Downstate Cluster
Chembio	100	Downstate Cluster
Antigenics	100	Downstate Cluster
All others	1,400	
Total	9,652	

Source: NYBA; annual reports; interviews

New York biotech employment over the past decade has quadrupled, growing at an annual compound growth of 15.4%.

Year	Total Employment
1997	2,300
2000	4,907
2002	6,340
2007	9,600

Source: NYBA

Clinical Development

New York State biotechnology companies combined currently have 282 pharmaceutical products in clinical development...

Preclinical	154
Phase I	57
Phase II	45
Phase III	23
Pre-reg	3
Marketed	19

Source: Recap.com; NYBA

Notable pipeline drugs include:

- Fampridine-SR (Acorda Therapeutics), a Phase III investigational oral, sustained-release tablet formulation of 4-aminopyridine for multiple sclerosis, has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged
- ZIO-101 (Ziopharm), a Phase II product for the treatment of patients with primary liver cancer
- VEGF Trap-Eye (Regeneron), a macular degeneration therapy, has shown a statistically significant reduction in retinal thickness, a measure of disease activity, after 12 weeks of treatment
- Methylalntrexone (Progenics), a Phase II drug designed to mitigate the effect of opioids on peripheral receptors without interfering with central nervous system pain relief
- KX2-391 (Kinex), a Phase I drug belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors
- EpiCept NP-1 cream (EpiCept) is a patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies

...and have launched a variety of new products and services

Marketing

- OSI Pharmaceuticals announced that Tarceva has been approved in Europe in combination with gemcitabine as first-line therapy for metastatic pancreatic cancer
- Had been previously approved by FDA in 2005
- Antigenics announced that Oncophage, the company's flagship cancer vaccine, has been approved in Russia for the treatment of kidney cancer, making it the first cancer vaccine approved for marketing

Joint Venture

- PsychoGenics announced a joint venture with Amylin Pharmaceuticals, Inc. to form Psylin Neurosciences, Inc., a new company focused on the discovery and development of peptide hormones for treatment of psychiatric disorders

Licensing

- Regeneron Pharmaceuticals unveiled the first licensing deal for its VelocImmune antibody discovery technology
- AstraZeneca paid Regeneron a \$20 million license fee for Regeneron's VelocImmune technology and will pay \$20 million per year over the next five years, for a potential of \$120 million

State Funding

- The first grant awards for New York State's \$600 million multi-year stem cell research program were approved

Government Sources of Funding for New York Biotechnology

Early stage research funding for New York State biotechnology comes from two key sources 1) New York State; 2) the US government.

New York State Funding

Empire State Development Corp.

\$2 million grant to Cold Spring Harbor Laboratories. The grant will help Cold Spring Harbor Laboratory purchase new equipment for its new \$200 million Hillside research complex, creating 80 high tech jobs over the next three years.

NYSTAR Technology Transfer Incentive Program

The Technology Transfer Incentive Program is specifically designed to help business make the rapid transfer of new ideas and new technology from the research lab to the marketplace. 7 projects totaling \$2.37 million.

NYSTAR James D. Watson Investigator Awards

Provides grants to outstanding early career scientists who demonstrate the potential for leadership at the frontiers of knowledge in the life sciences and demonstrate an entrepreneurial spirit to help foster economic development in New York State. 2002-2006, 43 grants totaling \$8.6 million.

New York State Stem Cell Initiative

\$600 million multi-year stem cell research program. First awards were made in January, 2008, providing \$6.1 million for direct stem cell research, \$7.4 million for stem cell research infrastructure, and \$1 million for stem cell research training.

NYSTAR Funding for New York Life Sciences Projects, 2005 - 2007

2007	\$8,072,900
2006	\$14,427,200
2005	\$10,644,730

Source: NYSTAR

In addition to direct research funding, New York biotech companies also took advantage of a variety of state tax incentives, including

- Qualified Emerging Technology Companies Credits (QETC)
- Investment Tax Credit / Employment Incentive Credit
- Capital Tax Credit
- Employment Tax Credit
- Facilities, Operations and Training Credit
- Empire Zones Credits


Federal Research Funding

National Institutes of Health Funding

In 2005, New York State was ranked third nationwide, behind California and Massachusetts, in the number of National Institute of Health grant awards provided to New York research institutions: 4,898 grants totaling \$2.72 billion.


Small Business Innovation Research Grants (SBIR)

Phase I SBIR funding for New York bioscience companies has remained relatively flat since 2000...



Phase I Bioscience SBIR Source: US Government publications, 2007

...but Phase II awards have tripled during the same period



Phase II Bioscience SBIR Source: US Government publications, 2007

Federal research dollars are one of New York's most important sources of biotech research funding, and the state ranks second overall in terms of university life sciences R&D expenditures.

Life Sciences R&D Expenditures at New York State Universities

	New York			United States			NY Rank	
	FY2003	FY2006	% change	FY2003	FY2006	% change	2003	2006
Life Sciences (\$ thousands)	\$2,147,286	\$2,500,186	16%	\$24,062,088	\$28,831,208	20%	2	2
Percent of Total R&D	69.5%	66.0%	(0.5%)	60.0%	60.3%	0.05%		

in US Thousands Source: National Science Foundation, 2007; NYBA

Top 15 New York State Universities in Life Sciences R&D Expenditures, FY2006

	Total R&D	Life Sciences R&D	Life Sciences % of total R&D	Life Sciences R&D National Rank
Cornell University all campuses	648,802	411,148	63.3%	14
Columbia University	529,945	367,877	69.4%	22
Mt. Sinai School of Medicine	273,216	273,216	100%	34
University of Rochester	366,658	234,547	63.9%	41
New York University	284,164	229,797	80.9%	43
SUNY Buffalo all campuses	297,909	212,496	71.3%	50
Rockefeller University	215,417	198,779	92.2%	52
Yeshiva University	189,416	189,416	100%	56
SUNY Stony Brook all campuses	234,635	97,924	41.7%	96
SUNY Albany	274,354	96,729	35.2%	97
SUNY Upstate Medical University	37,181	37,181	100%	
New York Medical College	34,397	34,397	100%	
SUNY Health Science Ctr. Brooklyn	31,064	31,064	100%	
Albany Medical Center	16,227	16,227	100%	
CUNY Hunter College	31,308	11,469	36.6%	

in US Thousands Source: National Science Foundation, 2007; NYBA

Biotech's Economic Impact on New York

With total impact of nearly \$8.5 billion, New York's bioscience* industry ranks fifth nationwide in terms of its contribution to the state's economy (\$US billions)...

Rank	State	Total Impact	Direct Impact	Indirect & Induced	Indirect Impact
1	New Jersey	22,198.51	10,173.26	12,025.25	7,645.61
2	California	21,227.55	9,637.88	11,589.67	6,293.25
3	Pennsylvania	15,812.85	7,341.69	8,471.15	5,210.58
4	Indiana	11,393.39	5,711.41	5,681.98	3,480.84
5	New York	8,449.77	4,501.78	3,948.00	2,201.14
6	North Carolina	9,374.50	4,493.25	4,881.25	2,849.46
7	Illinois	7,609.99	3,381.17	4,228.82	2,650.54
8	Massachusetts	4,822.64	2,351.62	2,471.03	1,225.61
9	Michigan	3,907.50	1,926.77	1,980.72	1,160.15
10	Connecticut	3,674.03	1,820.46	1,853.57	1,124.47
	All States	172,710.14	63,966.72	108,743.42	67,798.52

in \$US billions *includes all biosciences; Source: Milken Institute, 2006

...and returns more than half a billion in taxes back to the state

	State & Local Taxes	Federal Taxes	Total Taxes
Total Tax Receipts	514.3	1,248.10	1,762.30
Personal Income Tax Receipts	372.7	841.5	1,214.20
Sales Tax Receipts	29.3	-	29.3
Corporate Income Tax Receipts	112.2	406.5	518.8

in \$US millions Source: Milken Institute, 2006

New York Biotechnology Innovation

New York State academic institutions and companies generate a significant number of bioscience* patents, and the state consistently ranks in the top 5 states nationally in the number of biotech-related patents issued annually. While the USPTO has no single classification for biotechnology-related patents, such patents are largely found under four classes:

- Class 435, Chemistry: Molecular Biology and Microbiology
- Class 424, Drug, Bio-Affecting and Body Treating Compositions;
- Class 536, Organic Compounds (including DNA)*; and
- Class 800, Multicellular Living Organisms and Unmodified Parts Thereof and Related Processes

New York's most active overall biotechnology corporate patenters as identified by the US Patent and Trademark Office are listed here:

Assignee	2002	2003	2004	2005	2006	Total
Genencor International, Inc.	24	29	17	20	21	111
Regeneron Pharmaceuticals, Inc.	10	8	5	8	13	44
Emisphere Technologies, Inc.	9	4	1	3	5	22
Advion Biosciences, Inc.	0	4	10	5	0	19
OSI Pharmaceuticals Inc.	4	5	6	2	2	19
Progenics Pharmaceuticals, Inc.	3	1	3	1	6	14
Alteon Inc.	3	3	2	0	2	10
AMRI	5	2	1	0	0	8
Enzo Life Sciences, Inc.	0	1	2	1	3	7
Angiodynamics, Inc.	0	0	0	4	2	6
Penwest Pharmaceuticals Co.	1	1	3	1	0	6

Source: USPTO Patent Statistics Report, 2008; NYBA

In Class 435, Chemistry: Molecular Biology and Microbiology, Rochester's Genencor is the most active patenter among New York State organizations, having been issued an average of 22 patents per year from 2002 to 2006.

Assignee	2002	2003	2004	2005	2006	Total
Genencor International, Inc.	24	29	17	20	21	111
Columbia University	13	14	14	13	10	64
Cornell Research Foundation Inc.	9	15	11	12	13	60
Bristol-Myers Squibb	5	11	14	8	20	58
Ludwig Institute for Cancer Research	18	5	12	3	6	44
Pfizer Inc.	13	8	12	1	9	43
Rockefeller University	16	5	4	3	7	35
New York University	5	2	9	3	9	28
Regeneron Pharmaceuticals, Inc.	6	7	1	3	8	25
Sloan-Kettering Institute For Cancer Research	3	6	7	4	5	25
Research Foundation of State University of New York	5	2	7	2	6	22
Mt. Sinai School of Medicine	0	11	1	4	3	19
Albert Einstein College of Medicine of Yeshiva University	6	3	5	0	4	18
Corning Incorporated	1	6	5	2	4	18
University of Rochester	1	1	4	3	8	17

Source: USPTO Patent Statistics Report, 2008; NYBA

In Class 424, Drug, Bio-Affecting and Body Treating Compositions (includes Class 514), Pfizer is New York's leading patenter, with some 589 patents issued in this class from 2002-2006.

Assignee	2002	2003	2004	2005	2006	Total
Pfizer Inc.	133	137	107	128	84	589
Bristol-Myers Squibb	31	40	38	36	20	165
Columbia University	12	7	10	9	13	51
Cornell Research Foundation Inc.	7	9	7	10	12	45
Sloan-Kettering Institute for Cancer Research	8	12	6	8	7	41
Ludwig Institute for Cancer Research	9	11	7	0	3	30
Research Foundation of State University of New York	10	3	6	4	7	30

Source: USPTO Patent Statistics Report, 2008; NYBA

Recent Significant Events in New York Biotechnology

November 2007	PsychoGenics announces drug discovery agreement with Cephalon
October 2007	Cleveland BioLabs moves headquarters and operations from Cleveland, Ohio, to Buffalo, New York
October 2007	Groundbreaking ceremony for the \$700 million Alexandria Center for Science and Technology at the East River Science Park
October 2007	Pfizer's Chantix wins prize for Best Pharmaceutical Agent at the inaugural Prix Galien USA Prize Ceremony
October 2007	AMRI and Cystic Fibrosis Foundation Therapeutics, Inc. announce a four-year, \$23.7 million research collaboration
October 2007	Epicept raises \$7.3 million in secondary public offering
September 2007	Stony Brook University breaks ground on \$25 Million STAR Center for Biotechnology and Bioengineering
September 2007	Progenics raises \$57 million in secondary stock offering
August 2007	ImClone Systems receives approval from the FDA for a second facility to manufacture Erbitux
June 2007	Weill Cornell Medical College announces gifts totaling \$400 million toward a new 350,000-square-foot Biomedical Research Building in New York City
June 2007:	International AIDS Vaccine Initiative announces it is first tenant for Brooklyn's BioBAT facility
May 2007	IRX Therapeutics raises \$12.5 million through a second convertible note offering
April 2007	University at Albany and Taconic Farms announce \$13.2 million biotechnology expansion on the University of Albany East Campus
April 2007	Regeneron announces it is moving its headquarters to a new \$145 million facility in Tarrytown
February 2007	Cornell University receives \$10 million grant from the Empire State Development Corp. to upgrade Cornell's industrial biotechnology laboratories

New York as a Place To Build a Biotech Business

New York has ranked well nationally as a location for building a biotechnology business. In 2006, Business Facilities Magazine, a leading business publication for companies seeking to expand or relocate their companies, ranked New York first in the nation in the development of its biotechnology industry, calling the State the "best location for growing a biotechnology business."

More recently, FierceBiotech named New York the number two state for biotech (behind Texas, but beating out California and Massachusetts), noting that "New York did what other states talked about, approving \$600 million to back local embryonic and adult stem cell research projects."

Our own survey of New York biotechnology companies shows that the state received satisfactory ratings in most categories as a location for building a biotech business, but that there is concern in several areas, particularly regarding the regulatory and tax environment.

New York Performance in Determining Location of Business

Scale of 1 to 5; 5=most important	Importance to Business	New York Performance
Scientific Staff	4.6	3.4
Senior Staff	4	3.2
Specialized Staff	3.6	2.8
Quality of Life	3	3.2
Operational Costs	3.9	2.2
Access to University Facilities	2.8	3.5
Regulatory Environment	3	2.3
Tax Environment	2.9	1.8
Access to Other Companies	3	2.4
Access to Other Facilities	2.5	2.2
Access to Funding Sources	3	2.9
Access to Customers	2.9	2.4
Access to Suppliers	2.5	2.6

Source: NYBA Note: n = 33



New York State Bioscience Academic Centers and Research Facilities

The Center for Pharmacogenomics at Albany Medical College (ARC)

The Plant Proteomics-Metabolomics Facility at Cornell University (ARC)

The Center for Integrated Multilevel Analysis of Neuronal Plasticity at Mount Sinai School of Medicine (ARC)

Center for Advanced Information Management at Columbia University (CAT)

Center for Life Science Enterprise at Cornell University (CAT)

Center in Medical Biotechnology at Stony Brook University (CAT)

Center for Advanced Biomedical and Bioengineering Technologies at University at Buffalo (CAT)

Biomedical Research Laboratory at Albany Medical Center (Gen*NY*sis)

Biosurfaces Laboratory at Alfred University (Gen*NY*sis)

Advanced Biotechnologies Center at Binghamton University (Gen*NY*sis)

Broad Hollow Bioscience Park, Inc. (Gen*NY*sis)

Center for Assistive and Adaptive Technologies at Clarkson University (Gen*NY*sis)

Long Island Biotechnology Cluster at Cold Spring Harbor Laboratory (Gen*NY*sis)

Life Science Technology Center at Cornell University (Gen*NY*sis)

Biotechnology Research Center at CUNY College of Staten Island (Gen*NY*sis)

The Institute for the Development of Education in the Advanced Sciences at Hofstra University (Gen*NY*sis)

The Academic Center for Integrated Biological, Chemical and Technological Sciences

at Niagara University (Gen*NY*sis)

Center for Bioengineering and Medicine at Rensselaer Polytechnic Institute (Gen*NY*sis)

Center for Biotechnology Education and Training at Rochester Institute of Technology (Gen*NY*sis)

Central New York Biotechnology Research Center at SUNY Upstate (Gen*NY*sis)

Center for Immunology Research at Trudeau University (Gen*NY*sis)

Gen*NY*Sis Center for Excellence in Cancer Genomics at University at Albany Foundation (Gen*NY*sis)

Biomedical Research Center at University of Rochester (Gen*NY*sis)

Biotechnology Research Center at Yeshiva University (Gen*NY*sis)

The New York Structural Biology Center at City University of New York (STAR Center)

The Integrated Imaging Center at Columbia University (STAR Center)

Genomic Technologies & Information Sciences Center at Cornell University (STAR Center)

The Center in Biomolecular Diagnostics and Therapeutics at Stony Brook University (STAR Center)

The Center of Disease Modeling and Therapy Discovery at SUNY Buffalo (STAR Center)

The Nanobiotechnology Center at Cornell University

Institute for Lasers, Photonics and Biophotonics at SUNY Buffalo

Center of Excellence in Bioinformatics at University at Buffalo